PURPOSE: determine the value of MR studies in patients undergoing radiotherapy for glioblastomas pre and during radiotherapy to predict the clinical course. PATIENTS AND METHODS: MR follow-up studies were performed in 33 patients with glioblastomas before radiotherapy, after 30 Gy, after 60 Gy, and in the treatment follow-up. Findings on MR were categorized into: definite progress, questionable progress, status idem. Patients were followed clinically (median for 11 months). RESULTS: after 30 Gy 23/33 (70%) of the MR examination showed status idem. 10/33 (30%) demonstrated definite (n = 6) or questionable (n = 4) progress. Further tumor progress was faster in these patients and patients succumb to their disease earlier (9 vs. 22 months). The 60 Gy study showed definite (n = 8) and questionable (n = 6) progress in 14/33 (42%) cases. All these tumors were progressing faster and were associated with a comparatively reduced life expectancy. CONCLUSION: MR follow-up studies after 30 Gy in patients undergoing radiotherapy for glioblastomas allow for prognostic appraisal, and potentially early modification of treatment.
PURPOSE: determine the value of MR studies in patients undergoing radiotherapy for glioblastomas pre and during radiotherapy to predict the clinical course. PATIENTS AND METHODS: MR follow-up studies were performed in 33 patients with glioblastomas before radiotherapy, after 30 Gy, after 60 Gy, and in the treatment follow-up. Findings on MR were categorized into: definite progress, questionable progress, status idem. Patients were followed clinically (median for 11 months). RESULTS: after 30 Gy 23/33 (70%) of the MR examination showed status idem. 10/33 (30%) demonstrated definite (n = 6) or questionable (n = 4) progress. Further tumor progress was faster in these patients and patients succumb to their disease earlier (9 vs. 22 months). The 60 Gy study showed definite (n = 8) and questionable (n = 6) progress in 14/33 (42%) cases. All these tumors were progressing faster and were associated with a comparatively reduced life expectancy. CONCLUSION: MR follow-up studies after 30 Gy in patients undergoing radiotherapy for glioblastomas allow for prognostic appraisal, and potentially early modification of treatment.
Authors: J Y Pierga; K Hoang-Xuan; L Feuvret; J M Simon; P Cornu; F Baillet; J J Mazeron; J Y Delattre Journal: J Neurooncol Date: 1999-06 Impact factor: 4.130
Authors: Marta Brell; Avelina Tortosa; Eugenia Verger; Juan Miguel Gil; Nuria Viñolas; Salvador Villá; Juan José Acebes; Lluis Caral; Teresa Pujol; Isidro Ferrer; Teresa Ribalta; Francesc Graus Journal: Clin Cancer Res Date: 2005-07-15 Impact factor: 12.531
Authors: A Idbaih; S Taillibert; J-M Simon; D Psimaras; H-M Schneble; S Lopez; P Lang; T Toubiana; L Feuvret; J-Y Delattre; J-J Mazeron Journal: Cancer Radiother Date: 2008-11-28 Impact factor: 1.018
Authors: Marc D Piroth; Bernd Gagel; Michael Pinkawa; Sven Stanzel; Branka Asadpour; Michael J Eble Journal: Strahlenther Onkol Date: 2007-12 Impact factor: 3.621
Authors: J P Boström; M Seifert; S Greschus; N Schäfer; M Glas; G Lammering; U Herrlinger Journal: Strahlenther Onkol Date: 2014-01-17 Impact factor: 3.621
Authors: C Leitzen; T Wilhelm-Buchstab; L C Schmeel; S Garbe; S Greschus; T Müdder; S Oberste-Beulmann; B Simon; H H Schild; H Schüller Journal: Strahlenther Onkol Date: 2016-06-03 Impact factor: 3.621